top of page
Educational Videos
19 June 2024
HaemaLogiX CSO Dr Rosanne Dunn explains the key highlights of the abstract that was recently published on the European Hematology Association (EHA)
29 February 2024
Honouring Rare Disease Day: The Battle Against Multiple Myeloma and AL Amyloidosis
1 June 2023
Inside the KappaMab manufacturing process
22 December 2022
The latest on our CAR-T technology and more, presented at Myeloma Australia’s 4th National Myeloma Workshop
21 December 2022
Novel antigens LMA and KMA are expressed on malignant bone marrow plasma cells from patients at all stages of multiple myeloma
15 December 2022
What makes our immunotherapies different on the large and growing multiple myeloma treatment market
15 August 2022
Chief Manufacturing and Development Officer Tertia Dex explains the KappaMab manufacturing process
15 March 2022
HaemaLogiX's Mary Sartor's presentation to the 63rd Annual ASH Annual Meeting in Atlanta, Georgia 2021
16 February 2022
How KappaMab works. KappaMab is a monoclonal antibody developed by HaemaLogiX to treat blood cancers, with an initial focus on multiple myeloma.
bottom of page